JOHOR Baru City Council (MBJB) has announced the successful completion of a flood mitigation project in Kampung Oren, Ulu ...

Biocon Ltd’s share price fell 4.86 per cent on January 27, 2025, hitting a day’s low of Rs 369.40 on the NSE, while the NIFTY ...

The Global Risks Report 2025 highlights economic downturn as Malaysia’s top risk, alongside concerns over labour shortages, inflation, food supply issues, and unemployment. Malaysia is identified as ...

The deal involved an option to acquire up to a 3.81% stake in Biocon Biologics. Goldman Sachs AIF Scheme-1 (GS AIF) had acquired optionally convertible debentures (OCDs) from Biocon Biologics ...

India's Competition Commission has penalized Goldman Sachs' investment manager for not notifying a deal to acquire a stake in Biocon Biologics, citing potential strategic impact. New Delhi, Jan 16 ...

It's nothing that EV makers such as Tesla aren't already selling, but he and his buddies custom-engineered their product, made with Chinese phone parts, for Malaysia's national auto brands.

we believe Biocon is improving its execution, which is reflected in its market share gain for launched products. The FDA clearance for its Malaysia insulin plant on 12 January 2025 culminated its ...

HSBC noted that Biocon is well-positioned for growth, citing key developments such as the FDA clearance for its Malaysia insulin plant, which ends a long regulatory overhang and paves the way for the ...

HSBC highlighted several factors that could drive earnings growth, including the FDA’s recent clearance of Biocon’s Malaysia plant, which addresses prior concerns regarding Good Manufacturing ...

Over the weekend, the US Food and Drug Administration (FDA) reclassified Biocon’s Malaysia facility status to "Voluntary Action Indicated" (VAI), a significant improvement from the earlier "Official ...

The brokerage sees several factors supporting future earnings growth, including the FDA's clearance of Biocon’s Malaysia plant, which alleviates previous GMP concerns. The upcoming launch of aspart ...

The upgrade reflects a turnaround driven by biosimilar launches, improved generics sales, and US FDA clearance of Biocon’s Malaysia plant. HSBC's new target price represents a 48.3% increase, ...